DE602004009705D1 - Methoden der Verhinderung und Behandlung der Alzheimer'schen Krankheit - Google Patents
Methoden der Verhinderung und Behandlung der Alzheimer'schen KrankheitInfo
- Publication number
- DE602004009705D1 DE602004009705D1 DE602004009705T DE602004009705T DE602004009705D1 DE 602004009705 D1 DE602004009705 D1 DE 602004009705D1 DE 602004009705 T DE602004009705 T DE 602004009705T DE 602004009705 T DE602004009705 T DE 602004009705T DE 602004009705 D1 DE602004009705 D1 DE 602004009705D1
- Authority
- DE
- Germany
- Prior art keywords
- arg
- glu
- asp
- tyr
- phe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 5
- 230000002265 prevention Effects 0.000 title 1
- 229960005486 vaccine Drugs 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- RBXSZQRSEGYDFG-GUBZILKMSA-N Glu-Lys-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O RBXSZQRSEGYDFG-GUBZILKMSA-N 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 230000000324 neuroprotective effect Effects 0.000 abstract 1
- 230000001777 nootropic effect Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Marine Sciences & Fisheries (AREA)
- Toxicology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT362003 | 2003-01-14 | ||
| AT362003 | 2003-01-28 | ||
| AT14642003 | 2003-09-17 | ||
| AT0146403A AT413945B (de) | 2003-01-14 | 2003-09-17 | Impfstoff für die alzheimer-krankheit |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE602004009705D1 true DE602004009705D1 (de) | 2007-12-06 |
| DE602004009705T2 DE602004009705T2 (de) | 2008-06-05 |
Family
ID=32714004
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602004025668T Expired - Lifetime DE602004025668D1 (de) | 2003-01-14 | 2004-01-13 | Methoden der verhinderung und behandlung der alzheimer'schen krankheit |
| DE602004009705T Expired - Lifetime DE602004009705T2 (de) | 2003-01-14 | 2004-01-13 | Methoden der Verhinderung und Behandlung der Alzheimer'schen Krankheit |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602004025668T Expired - Lifetime DE602004025668D1 (de) | 2003-01-14 | 2004-01-13 | Methoden der verhinderung und behandlung der alzheimer'schen krankheit |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US7732568B2 (de) |
| EP (2) | EP1583774B1 (de) |
| JP (2) | JP4547373B2 (de) |
| CN (2) | CN1826354B (de) |
| AT (3) | AT413945B (de) |
| CA (1) | CA2513218C (de) |
| CY (2) | CY1107146T1 (de) |
| DE (2) | DE602004025668D1 (de) |
| DK (2) | DK1679319T3 (de) |
| ES (2) | ES2296084T3 (de) |
| HK (1) | HK1091499A1 (de) |
| PL (1) | PL209989B1 (de) |
| PT (2) | PT1583774E (de) |
| SI (1) | SI1583774T1 (de) |
| WO (1) | WO2004062556A2 (de) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003303198A1 (en) | 2002-12-19 | 2004-07-14 | New York University | Method for treating amyloid disease |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| AT413336B (de) * | 2003-09-12 | 2006-02-15 | Mattner Frank Dr | Apherese-vorrichtung |
| JP2007522119A (ja) * | 2004-01-28 | 2007-08-09 | キュリックス エーピーエス | アミロイド関連疾患用ワクチンとしてのアミロイドタンパク質のコンジュゲート |
| AT500483B1 (de) | 2004-07-13 | 2006-01-15 | Mattner Frank Dr | Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung |
| AT413946B (de) * | 2004-07-13 | 2006-07-15 | Mattner Frank Dr | Impfstoff gegen die alzheimer-krankheit |
| PT1954718E (pt) | 2005-11-30 | 2014-12-16 | Abbvie Inc | Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos |
| DK1976877T4 (en) | 2005-11-30 | 2017-01-16 | Abbvie Inc | Monoclonal antibodies to amyloid beta protein and uses thereof |
| KR20150098683A (ko) * | 2005-12-12 | 2015-08-28 | 에이씨 이뮨 에스.에이. | 치료적 특성을 갖는 베타 1-42 특이적인 단일클론성 항체 |
| EP1878747A1 (de) | 2006-07-11 | 2008-01-16 | greenovation Biotech GmbH | Glyco-hergestellte Antikörper |
| SG173385A1 (en) | 2006-07-14 | 2011-08-29 | Ac Immune S A Ch | Humanized antibody against amyloid beta |
| US8455626B2 (en) * | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| WO2008104386A2 (en) | 2007-02-27 | 2008-09-04 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
| RU2567151C2 (ru) * | 2007-06-12 | 2015-11-10 | Ац Иммуне С.А. | Гуманизированные антитела к амилоиду бета |
| US8048420B2 (en) * | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| AU2008311367B2 (en) * | 2007-10-05 | 2014-11-13 | Ac Immune S.A. | Use of anti-amyloid beta antibody in ocular diseases |
| AU2008311366B2 (en) * | 2007-10-05 | 2015-03-12 | Ac Immune S.A. | Use of anti-amyloid beta antibody in ocular diseases |
| SG185277A1 (en) * | 2007-10-05 | 2012-11-29 | Genentech Inc | Humanized antibody |
| US8586706B2 (en) * | 2007-10-25 | 2013-11-19 | Kagoshima University | Peptide vaccine using mimic molecules of amyloid β peptide |
| US8445649B2 (en) * | 2007-10-29 | 2013-05-21 | Tao Health Life Pharma Co., Ltd. | Antibody and use thereof |
| US8546532B2 (en) | 2008-04-17 | 2013-10-01 | Declion Pharmaceuticals, Inc. | Synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders |
| KR20110036809A (ko) * | 2008-06-12 | 2011-04-11 | 아피리스 아게 | 파킨슨병과 관련된 증상을 치료하기 위한 화합물 |
| AT509611B1 (de) * | 2008-06-12 | 2012-04-15 | Affiris Forschungs-Und Entwicklungs Gmbh | Vakzin |
| AT506819B1 (de) * | 2008-06-12 | 2011-06-15 | Affiris Forschungs Und Entwicklungs Gmbh | Vakzin zur behandlung von alzheimer-krankheit |
| MX360403B (es) | 2010-04-15 | 2018-10-31 | Abbvie Inc | Proteinas de union a amiloide beta. |
| CN103179981B (zh) | 2010-07-30 | 2017-02-08 | Ac免疫有限公司 | 安全和功能性的人源化抗β‑淀粉样蛋白抗体 |
| EP2603524A1 (de) | 2010-08-14 | 2013-06-19 | AbbVie Inc. | Amyloid-beta-bindende proteine |
| US20120328605A1 (en) * | 2010-10-27 | 2012-12-27 | Daniel Larocque | Compositions and uses |
| GB201113570D0 (en) * | 2011-08-05 | 2011-09-21 | Glaxosmithkline Biolog Sa | Vaccine |
| PT2579042E (pt) | 2011-10-04 | 2014-09-09 | Affiris Ag | Método para detecção de anticorpos específicos para a numa amostra biológica. |
| EP2787347A1 (de) | 2013-04-03 | 2014-10-08 | Affiris AG | Verfahren zur Erkennung von Aß-spezifischen Antikörpern in einer biologischen Probe |
| US10381614B2 (en) * | 2013-04-17 | 2019-08-13 | Samsung Sdi Co., Ltd. | Battery module |
| WO2015165961A1 (en) | 2014-04-29 | 2015-11-05 | Affiris Ag | Treatment and prevention of alzheimer's disease (ad) |
| WO2017076873A1 (en) | 2015-11-03 | 2017-05-11 | Affiris Ag | Method for vaccination against a self-antigen in a human patient |
| CN105237628B (zh) * | 2015-11-17 | 2018-08-07 | 南开大学 | 一种用于治疗阿尔兹海默症的多肽 |
| CN107022019B (zh) * | 2016-11-24 | 2020-10-30 | 桂林医学院 | 一种用于脑内降铁除自由基的多肽、制备方法与应用 |
| WO2023161526A1 (en) | 2022-02-28 | 2023-08-31 | Tridem Bioscience Gmbh & Co Kg | A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK590288D0 (da) * | 1988-10-24 | 1988-10-24 | Symbicom Ab | Kemiske forbindelser |
| US5650489A (en) * | 1990-07-02 | 1997-07-22 | The Arizona Board Of Regents | Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof |
| GB9022190D0 (en) | 1990-10-12 | 1990-11-28 | Perham Richard N | Immunogenic material |
| US5639603A (en) * | 1991-09-18 | 1997-06-17 | Affymax Technologies N.V. | Synthesizing and screening molecular diversity |
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| US6088993A (en) | 1999-02-05 | 2000-07-18 | Irace; Francisco D. | Closure system |
| JP2002537354A (ja) * | 1999-02-25 | 2002-11-05 | スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム | ペプチド、及びＨ．ｉｎｆｌｕｅｎｚａｅのプロテインＤ由来の担体を含む免疫原 |
| US6703491B1 (en) * | 1999-03-17 | 2004-03-09 | Exelixis, Inc. | Drosophila sequences |
| DE60044057D1 (de) * | 1999-09-03 | 2010-05-06 | Univ Ramot | Verbindungen, zusammensetzungen und verfahren zur behandlung oder vorsorge von alzheimer erkrankung |
| IL151355A0 (en) | 2000-03-03 | 2003-04-10 | Smithkline Beecham Biolog | Vaccine for the treatment of artherosclerosis |
| GB0024200D0 (en) * | 2000-10-03 | 2000-11-15 | Smithkline Beecham Sa | Component vaccine |
| DE50111493D1 (de) | 2001-09-03 | 2007-01-04 | Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh | Antigen-Mimotope und Vakzine gegen Krebserkrankungen |
| DE60216048T2 (de) * | 2002-05-07 | 2007-05-31 | Institut Pasteur | Screeningverfahren für Peptide, die die Bindung von PP1c an Bcl-2, BCL-Xl und BCL-W Proteine inhibieren |
-
2003
- 2003-09-17 AT AT0146403A patent/AT413945B/de not_active IP Right Cessation
-
2004
- 2004-01-13 DK DK05107898T patent/DK1679319T3/da active
- 2004-01-13 DE DE602004025668T patent/DE602004025668D1/de not_active Expired - Lifetime
- 2004-01-13 ES ES05107898T patent/ES2296084T3/es not_active Expired - Lifetime
- 2004-01-13 CN CN200480002213.2A patent/CN1826354B/zh not_active Expired - Fee Related
- 2004-01-13 EP EP04701585A patent/EP1583774B1/de not_active Expired - Lifetime
- 2004-01-13 ES ES04701585T patent/ES2339447T3/es not_active Expired - Lifetime
- 2004-01-13 DE DE602004009705T patent/DE602004009705T2/de not_active Expired - Lifetime
- 2004-01-13 SI SI200431399T patent/SI1583774T1/sl unknown
- 2004-01-13 JP JP2006500553A patent/JP4547373B2/ja not_active Expired - Fee Related
- 2004-01-13 DK DK04701585.4T patent/DK1583774T3/da active
- 2004-01-13 EP EP05107898A patent/EP1679319B1/de not_active Expired - Lifetime
- 2004-01-13 AT AT05107898T patent/ATE376559T1/de active
- 2004-01-13 WO PCT/EP2004/000162 patent/WO2004062556A2/en active Application Filing
- 2004-01-13 CA CA2513218A patent/CA2513218C/en not_active Expired - Fee Related
- 2004-01-13 AT AT04701585T patent/ATE458753T1/de active
- 2004-01-13 PL PL378333A patent/PL209989B1/pl unknown
- 2004-01-13 US US10/540,551 patent/US7732568B2/en not_active Expired - Fee Related
- 2004-01-13 PT PT04701585T patent/PT1583774E/pt unknown
- 2004-01-13 CN CN2011103110387A patent/CN102526699A/zh active Pending
- 2004-01-13 PT PT05107898T patent/PT1679319E/pt unknown
-
2006
- 2006-10-27 HK HK06111905.5A patent/HK1091499A1/xx not_active IP Right Cessation
-
2008
- 2008-01-17 CY CY20081100069T patent/CY1107146T1/el unknown
-
2010
- 2010-03-08 JP JP2010051012A patent/JP5282058B2/ja not_active Expired - Fee Related
- 2010-04-01 US US12/752,451 patent/US20110015131A1/en not_active Abandoned
- 2010-05-07 CY CY20101100399T patent/CY1110634T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE376559T1 (de) | Methoden der verhinderung und behandlung der alzheimer'schen krankheit | |
| TW200602071A (en) | Methods for preventing and treating alzheimer's disease (ad) | |
| AT500379B1 (de) | Tau-proteine | |
| NO20045021L (no) | Immunologiske metoder og preparater for behandling av Alzheimers sykdom | |
| DK1368060T3 (da) | HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme | |
| ATE283289T1 (de) | Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten | |
| NO20022531L (no) | Vaksine for forebyggelse og behandling av Alzheimer- og amyloidrelaterte sykdommer | |
| BRPI0513959A (pt) | anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos | |
| AU2002302255A1 (en) | Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases | |
| EA200702093A1 (ru) | Антитела-миметики glp-1 человека, композиции, способы и их применение | |
| NO20076021L (no) | Antistoffer rettet mot amyloid-betapeptid og metoder som anvender de samme | |
| SE0103754L (sv) | Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid | |
| BR0211296A (pt) | Peptìdeo imunogênico derivado da proteìna g do vrs do sub-grupo a ou b, sequência de ácido nucleico, composição farmacêutica, anticorpos policlonais ou monoclonais, kit de diagnóstico, utilização de um peptìdeo imunogênico, e, conjugado | |
| WO2001068708A3 (en) | Human and humanized fap-alpha-specific antibodies | |
| WO2004006952A3 (en) | Therapeutic tuberculosis vaccines | |
| DE60313437D1 (de) | Mhc klasse i peptidepitope des humanen tumorassoziierten antigens 5t4 | |
| EP2628750A3 (de) | Gezielte Identifikation von immunogenen Peptiden | |
| NO20052525D0 (no) | Spleisevariant av humant hypofyseveksthormon | |
| WO2007030771A3 (en) | Targeted identification of immunogenic peptides | |
| ATE338063T1 (de) | Diagnostische verwendungen des t-zell proteins tzon7, der davon abgeleiteten peptide und des antikörpers | |
| ATE512981T1 (de) | Identifizierung von ses-3 (spr-5) aus c. elegans sowie dessen verwendungen | |
| ATE349532T1 (de) | Zytotoxisches t-zellepitop des papillomavirus l1- proteins und seine verwendung in diagnostik und therapie | |
| WO2007023189A3 (en) | Pharmaceutical composition and its use for the prophylactic or therapeutic treatment of retroviral diseases | |
| WO2002008393A3 (en) | Serine protease from yersinia enterocolitica | |
| DE50210281D1 (de) | Identifizierung von ses-1 aus c. elegans sowie dessen verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8327 | Change in the person/name/address of the patent owner |
Owner name: AFFIRIS AG, WIEN, AT |